|
Research Highlights
VA Testing Therapy for Lou Gehrig’s Disease
April 5, 2005
Patients with amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, are being recruited for a nationwide VA study testing the safety of a drug that has yielded promising results in animal research. Participants will receive sodium phenylbutyrate over five months. The drug, long used as a cancer therapy, significantly extended the lives of mice with ALS in a recent study. ALS is a progressive, fatal neurological disease that affects up to 30,000 Americans. It kills nerve cells in the brain and spinal cord that control muscle movement, resulting in gradual muscle wasting and loss of movement. For more information about the study call (781) 687-2884 or visit www.alsa.org, the website of the ALS Association, and look under “Drug Trials.”
|
